248 related articles for article (PubMed ID: 31244112)
1. (
Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
[TBL] [Abstract][Full Text] [Related]
2. Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.
Xiang HY; Wang X; Chen YH; Zhang X; Tan C; Wang Y; Su Y; Gao ZW; Chen XY; Xiong B; Gao ZB; Chen Y; Ding J; Meng LH; Yang CH
Eur J Med Chem; 2021 Jan; 209():112913. PubMed ID: 33109399
[TBL] [Abstract][Full Text] [Related]
3. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Beaufils F; Cmiljanovic N; Cmiljanovic V; Bohnacker T; Melone A; Marone R; Jackson E; Zhang X; Sele A; Borsari C; Mestan J; Hebeisen P; Hillmann P; Giese B; Zvelebil M; Fabbro D; Williams RL; Rageot D; Wymann MP
J Med Chem; 2017 Sep; 60(17):7524-7538. PubMed ID: 28829592
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Rageot D; Bohnacker T; Melone A; Langlois JB; Borsari C; Hillmann P; Sele AM; Beaufils F; Zvelebil M; Hebeisen P; Löscher W; Burke J; Fabbro D; Wymann MP
J Med Chem; 2018 Nov; 61(22):10084-10105. PubMed ID: 30359003
[TBL] [Abstract][Full Text] [Related]
5. 4-(Difluoromethyl)-5-(4-((3
Borsari C; Keles E; Rageot D; Treyer A; Bohnacker T; Bissegger L; De Pascale M; Melone A; Sriramaratnam R; Beaufils F; Hamburger M; Hebeisen P; Löscher W; Fabbro D; Hillmann P; Wymann MP
J Med Chem; 2020 Nov; 63(22):13595-13617. PubMed ID: 33166139
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
[TBL] [Abstract][Full Text] [Related]
8. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.
Venkatesan AM; Dehnhardt CM; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham RT; Chaudhary I; Mansour TS
J Med Chem; 2010 Mar; 53(6):2636-45. PubMed ID: 20166697
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
10. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors.
Wu TT; Guo QQ; Chen ZL; Wang LL; Du Y; Chen R; Mao YH; Yang SG; Huang J; Wang JT; Wang L; Tang L; Zhang JQ
Eur J Med Chem; 2020 Oct; 204():112637. PubMed ID: 32717477
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity.
Liao W; Wang Z; Han Y; Qi Y; Liu J; Xie J; Tian Y; Lei Q; Chen R; Sun M; Tang L; Gong G; Zhao Y
Eur J Med Chem; 2020 Jul; 197():112309. PubMed ID: 32375077
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Zhang J; Lv X; Ma X; Hu Y
Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
17. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.
Venkatesan AM; Chen Z; dos Santos O; Dehnhardt C; Santos ED; Ayral-Kaloustian S; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Chaudhary I; Mansour TS
Bioorg Med Chem Lett; 2010 Oct; 20(19):5869-73. PubMed ID: 20797855
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.
Yan G; Pu C; Lan S; Zhong X; Zhou M; Hou X; Yang J; Shan H; Zhao L; Li R
Eur J Med Chem; 2019 Sep; 178():667-686. PubMed ID: 31228810
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
20. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
